Benefit of Bevacizumab in Glioblastoma Under Discussion

This past year, ABC2 called upon the FDA, Genentech and the NCI’s Radiation Therapy Oncology Group, to harmonize the data generated in the various Avastin trials. 

Coordination between the groups would provide better data for the FDA as it considers final approval for the use of Avastin in treating GBM.  It would also provide better information for patients and physicians regarding the risks and benefits of using Avastin to treat GBM. 

This topic continues to draw a lot of attention in the field. 

Click HERE to read a recent article from Medscape discussing an article released in the February 20 issue of the New England Journal of Medicine on this topic.  ABC2’s petitioning of the FDA is noted.

 

 

 

Share |
October 21, 2014 09:33 PM
ABC2 CEO Max Wallace chaired the gathering of NCI experts and cancer advocates.
October 15, 2014 12:44 PM
Principal Investigators, based in the state of Florida, are invited to apply. Proposal deadline: December 15, 2014. 
October 14, 2014 12:50 PM
ABC2 funds project between UC San Diego Health System and Regulus Therapeutics Inc.

Join us in our fight for a cure!

Twitter